Comparison of FOLFOX and FOLFIRI adjuvant chemotherapy regimens in the treatment of colorectal mucinous adenocarcinoma

Objective To evaluate the clinical effect of FOLFOX regimen and FOLFIRI regimen in the treatment of colorectal mucinous adenocarcinoma after operation. Methods 40 patients confirmed mucinous adenocarcinoma by surgery and pathology were divided randomly into two groups. Twenty patients (Group FOLFOX) were treated with oxaliplatin combined with 5-fluorouracil, while the other Twenty patients (Group FOLFIRI) were treated with irinotecan combined with 5-fluorouracil. The progression free survival (PFS) of two groups was compared. Survival was estimated using the Kaplan-Meier method. Results The PFS of Group FOLFOX is 13 months, while the PFS of Group FOLFIRI is 18 months. Differences are statistically significant (χ2=4.294, P=0.038). Conclusion Colorectal mucinous adenocarcinoma after operation treated with FOLFIRI regimen can prolong PFS than FOLFOX regimen. Key words: Colorectal neoplasms; Therapy; Mucinous adenocarcinoma; Adjuvant chemotherapy